Comparative Pharmacology
Head-to-head clinical analysis: BACTOCILL IN PLASTIC CONTAINER versus PENICILLIN 2.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BACTOCILL IN PLASTIC CONTAINER versus PENICILLIN 2.
BACTOCILL IN PLASTIC CONTAINER vs PENICILLIN-2
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Bactericidal; inhibits cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidase activity essential for peptidoglycan cross-linking.
Inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidase activity, and activating autolytic enzymes.
1-2 g intravenously every 4 hours.
250 mg orally every 6 hours or 500 mg orally every 8 hours for mild to moderate infections; intravenous dosing: 1-2 million units every 4-6 hours.
None Documented
None Documented
30-60 minutes (mean 40 min) in adults with normal renal function; prolonged to 7-10 hours in anuria. Clinical context: dosing interval adjustment required in renal impairment.
30-60 minutes; prolonged in renal impairment (up to 10 hours in anuria)
Primarily renal (60-70% unchanged by tubular secretion and glomerular filtration); biliary/fecal excretion accounts for <30%.
Renal: 60-80% unchanged; biliary/fecal: minor (10-20%)
Category C
Category C
Penicillin Antibiotic
Penicillin Antibiotic